GlobeImmune Inc. (NasdaqCM:GBIM) is evaluating strategic options for the company. The Board has authorized eliminating the majority of positions in its workforce. These steps are not expected to have an impact on ongoing clinical trials being conducted by its collaborators in oncology and hepatitis B. GlobeImmune does not have a defined timeline for the strategic review process and is not confirming that the review will result in any specific action or transaction.